Drug intelligence / Profile preview

Cadelius D

Development stage: Unknown
Lead developer: Asac Pharmaceutical Immunology
Modality: Small Molecules
Administration: Oral

Overview

Cadelius D is a marketed fixed-dose combination pharmaceutical product developed by the Spanish company ASAC Pharma. It consists of calcium carbonate and vitamin D3 (colecalciferol), formulated as orodispersible tablets. The product is indicated for the treatment of osteoporosis and the prevention and treatment of calcium and vitamin D deficiencies, particularly in the elderly. Calcium carbonate serves as a source of elemental calcium for bone mineralization, while vitamin D3 acts as an agonist at the vitamin D receptor (VDR) to enhance intestinal calcium absorption and regulate bone metabolism. It is available in strengths of 600 mg calcium/1000 IU vitamin D3 and 600 mg calcium/2000 IU vitamin D3 and is reimbursed by the Spanish social security system.

Brand names: Cadelius D
Other names: Cadelius d

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Cadelius D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cadelius D.

Explore the full profile